PhotoCure - Results third quarter 2004
Hexvix® Receives First Marketing Approval
PhotoCure ASA (Oslo Stock Exchange: PHO) publishes today its results for the third quarter 2004. Highlights from the report include:
- Hexvix® is PhotoCure's second pharmaceutical product to receive marketing approval
- Metvix® approved in 8 new European countries, the product is now approved in a total of 29 countries
- Metvix sales amounted to 5975 units in the third quarter of 2004, up from 3055 units in third quarter of 2003 (+96%)
- Sales revenues increased to NOK 8.1 million in the third quarter 2004, compared to NOK 5.2 million in the corresponding quarter of 2003 (+56%).
- Net profit amounted to NOK 14.1 million compared to a net loss of NOK 14.8 in the third quarter of 2003. Adjusted for a one-off milestone revenue of NOK 25.3 million, net loss in the third quarter of 2004 totalled NOK 11.3 million. Liquid funds totalled NOK 153.5 million as of 30 September 2004.
President and CEO of PhotoCure, Vidar Hansson commented: "The most important event during this quarter is the approval of Hexvix in Sweden. Hexvix imaging of bladder cancer represents a great commercial opportunity for PhotoCure."
The full report for the third quarter 2004 and a presentation is available on www.photocure.com under Investors/Reports and presentations.
The report is also available at the following link:
http://hugin.info/131151/R/964768/139837.pdf
http://hugin.info/131151/R/964768/139837.pdf
The third quarter presentation is available at the following link:
PhotoCure ASA is a Norwegian listed company (Oslo Stock Exchange: PHO) that develops and sells pharmaceuticals and medical devices for photodynamic treatment of cancer and precancerous conditions. The company develops products for internal cancer, skin cancer and other skin diseases. Metvix is developed for the treatment of basal cell carcinoma (skin cancer) and actinic keratosis (precancerous skin lesions). PhotoCure is responsible for sales and marketing of Metvix in the Nordic countries, while its licensee, the global dermatology specialist, Galderma, is responsible for sales and marketing of Metvix in the rest of the world. PhotoCure's second pharmaceutical product Hexvix is approved for bladder cancer detection in Sweden and phase III studies are ongoing in the US.
PhotoCure, the PhotoCure logo, Aktilite, Metvix and Hexvix are trademarks or registered trademarks of PhotoCure ASA.
For further information, contact:
PhotoCure ASA
Attn. Vidar Hansson, CEO
Hoffsveien 48
NO-0377 Oslo
E-mail: vh@photocure.no